

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/615,119 **TRANSMITTAL** July 7, 2003 Filing Date **FORM** Carmel M. LYNCH First Named Inventor Not Yet Assigned Art Unit (to be used for all correspondence after initial filing) Not Yet Assigned **Examiner Name** Attorney Docket Number | 226272003901 Total Number of Pages in This Submission.

Total Number of Pages III This Submis	SSIOIT TO Attorney Bocket Humi	22027200301					
	ENCLOSURES (check all	that apply)					
Fee Transmittal Form	Drawing(s)	After Allowance Communication to Group					
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences					
Amendment/Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)					
After Final	Petition to Convert to a Provisional Application	Proprietary Information					
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter					
Extension of Time Request	Terminal Disclaimer	X Other Enclosure(s) (please identify below):					
Express Abandonment Request	Request for Refund	Form PTO-1449 (6 pages) Return postcard					
x Information Disclosure Statement (3 pages)	CD, Number of CD(s)						
Certified Copy of Priority Document(s)							
Response to Missing Parts/ Incomplete Application	Remarks						
Response to Missing Parts under 37 CFR 1.52 or 1.53							
SIGN	ATURE OF APPLICANT, ATTORNEY, OR	AGENT					
lor 1	MORRISON & FOERSTER LLP Customer No. 25226 Catherine M. Polizzi - 40,130						
Signature Colliere	Signature Cashiere M. Bi.						
September 23, 2003							

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: 9/23/03 Signature:	





CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22#13-1450, on September 3, 2003.

Laura Shires

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Carmel M. LYNCH et al.

Serial No.:

10/615,119

Filing Date:

July 7, 2003

For:

AMPLIFIABLE ADENO-ASSOCIATED

VIRUS (AAV) PACKAGING

CASSETTES FOR THE PRODUCTION OF RECOMBINANT AAV VECTORS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/180,114, filed October 20, 1998, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R.

§1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

	This In	formation Disclosure Statement is submitted:
	With	the application; accordingly, no fee or separate requirements are required.
	Befor	e the mailing of a first Office Action after the filing of a Request for Continued
	Exam	ination under § 1.114.
\boxtimes	Withi	n three months of the application filing date or before mailing of a first Office
	Actio	n on the merits; accordingly, no fee or separate requirements are required.
	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Actio	n or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
		is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmitta
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does

not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 226272003901. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated:

September 23, 2003

Respectfully submitted,

Catherine M. Polizzi Registration No. 40,130

Morrison & Foerster LLP 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-5651 Facsimile: (650) 494-0792

Form PTO-1449
O'INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 226272003901	Application Number 10/615,119
Applicant	
Carmel	M. LYNCH et al.
Filing Date July 7, 2003	Group Art Unit Not Yet Assigned
Mailing Date September 3 2003	

RADENA

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12/22/1992	5,173,414	Lebkowki et al.			
	2.	10/11/1994	5,354,678	Lebkowki et al.			
	3.	12/24/1996	5,587,308	Carter et al.			
	4.	08/19/1997	5,658,776	Flotte et al.			
	5.	11/17/1998	5,837,484	Trempe et al.			
	6.	02/09/1999	5,869,305	Samulski et al.			
	7.	11/23/1999	5,990,279	Carter et al.			
	8.	01/15/2002	6,338,962	Boyce			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Transl YES	ation NO
	9.	11/19/1995	EP 0 488 528	Europe				
	10.	05/29/1992	WO 92/08796	WIPO				
	11.	06/23/1994	WO 94/13788	WIPO				
	12.	12/08/1994	WO 94/28143	WIPO				
	13.	03/09/1995	WO 95/06743	WIPO				
	14.	05/18/1995	WO 95/13365	WIPO				
	15.	05/18/1995	WO 95/13392	WIPO				
	16.	06/01/1995	WO 95/14771	WIPO				
	17.	08/03/1995	WO 95/20671	WIPO				
	18.	01/11/1996	WO 96/00587	WIPO				
	19.	06/13/1996	WO 96/17947	WIPO	·			
	20.	03/13/1997	WO 97/09441	WIPO				
	21.	03/13/1997	WO 97/09442	WIPO				
	22.	09/12/1997	WO 97/32990	WIPO				

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTQ-1449			Docket Number 226272003901 Application Num		nber 10/615,119				
INFORMATION DISCLOSURE CITATION			Applicant						
in an application				Carmel M. LYNCH et al.					
SEP 2 6 2003 (Use several sheets if necessary)			Filing Date July 7, 2003		Group Art Unit	Not Yet Assig	gned		
			Mailing Date September	3, 2003					
BADEN									
	23.	06/25/1998	WO 98/27204	WI	PO		 		
	24. 03/11/1999 WO 99/11764 WI			WI	PO				
			OTHE	R D	OCUMENTS	(includi	ng author, title, Da	ite, Pertinent I	Pages, Etc.)
Examiner Initials	Ref. No.	Title							
	25.	1 '	et al., (May 1996) "I irol. 70(5):3235-324		o model of adeno-as	sociated vi	rus vector per	sistence a	nd
	26.	Antoni, B.A. immunodefic	et al., (January 1991 ciency virus type 1 pr) "A coduc	deno-associated virus	s rep protei Journal o	in inhibits hun f Virology 65	nan (1):396-40	14.
	27.	Arispe, N. et al., (March 1992) "Intrinsic anion channel activity of the recombinant first nucleotide binding fold domain of the cystic fibrosis transmembrane regulator protein" <i>Proc. Natl. Acad. Sci. USA</i> , Cell Biology, 89:1539-1543.							
	28.	Ausubel, F.M. et al., eds. (1987) <u>Current Protocols in Molecular Biology</u> , John Wiley & Sons, Inc., Table of Contents: pp. iii-xii.							
	29.	Berns, K.I. (1990) "Chapter 62: Parvoviridae and their replication" <u>Virology.</u> Volume 2, Fields, B.N. et al. (eds.), Raven Press (New York), pp. 1743-1763.							
	30.	Blacklow, N.R. (1988) "Chapter 11 Adeno-associated viruses of humans" Parvoviruses and Human Disease, J.R. Pattison (ed.), CRC Press, Inc., pp. 165-174.							
	31.	Boshart, M. et al., (June 1985) "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus" Cell 41:521-530.							
	32.	Boulikas, T. (1996) "Common structural features of replication origins in all life forms" J. Cell. Biochem. 60:297-316.							
	33.	Carter, B.J. (1989) "Chapter 18: Parvoviruses as vectors" <u>Handbook of Parvoviruses</u> , Volume II, Tijssen, P. (ed.) CRC Press, Boca Raton, FL, pp. 247-284.							
	34.	Carter, B.J. (1992) "Adeno-assoc	iated	virus vectors" Curre	ent Opinio	ns in Biotechn	ology <u>,</u> 3:5	33-539.
	35.	Carter, B.J. (1989) "Chapter 11: AAV DNA replication, integration, and genetics" Handbook of Parvoviruses, Volume I, Tijssen, P. (ed.) CRC Press, Boca Raton, FL, pp. 169-226.							
	36.	6. Chatterjee, S. et al., (1991) "Transduction of intracellular resistance to HIV production by an adeno-associated virus-based antisense vector" Vaccines 91, Cold Spring Harbor Laboratory Press, Chanock, R.M. et al. (eds.), pp. 85-90.							
	37.	Chatterjee, S. et al., (November 27, 1992) "Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector" Science 258:1485-1488.							
Chejanovsky, N. and Carter, B.J. (1989) "Mutagenesis of an AUG codon in the adeno-associate virus rep gene: Effects on viral DNA replication" Virology 173:120-128.						ate virus			
EXAMI	NER:				DATE CONSI	DERED:			
	EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.						citation if no	ot in	

PTO/SB/ 08 (2-92) pa- 820862

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

IN AN APPLICATION

Applicant

Carmel M. LYNCH et al.

Filing Date July 7, 2003

Docket Number 226272003901

Group Art Unit Not Yet Assigned

Application Number 10/615,119

	(Use several sneets if necessary)	Fining Date July 7, 2005 Group Art Ont Not 1ct Assigned			
		Mailing Date September 3, 2003			
·					
39		94) "Long-term biological response of injured rat carotid artery xpressing retrovirally introduced human genes" J. Clin. Invest.			
4(O. Coligan, J.E. et al., eds., (1998) in Inc., Table of Contents: pp. 1-9.	Coligan, J.E. et al., eds., (1998) in <u>Current Protocols in Immunology</u> . Volume 1, John Wiley & Sons, Inc., Table of Contents: pp. 1-9.			
4	1. Colowick, P. (ed. in chief) et al., (Academic Press, Table of Contents	1979) Methods in Enzymology, Volume LVIII, Cell Culture, s: v-viii.			
42	2. Diffley, J. (1996) "Once and only replication in eukaryotic cells" Ge	once upon a time: specifying and regulating origins of DNA enes & Devel. 10:2819-2830.			
43		"Defective regulation of outwardly rectifying Cl channels by tion of CFTR" <i>Nature</i> 358:581-584.			
4		on microscopic methods for locating the origin and termination ods in Enzymology, Volume 65, Grossman, L. and Moldave, K. pp. 709-717.			
4.	5. Flotte, T.R. et al., (1992) "Gene excells" Am. J. Respir. Cell. Mol. Bi	spression from adeno-associated virus vectors in airway epithelial ol. 7:349-356.			
4		ion of the cystic fibrosis transmembrane conductance regulator is promoter" <i>J. Biol. Chem.</i> 268(5):3781-3790.			
4		3) "Stable in vivo expression of the cystic fibrosis transmembrane no-associate virus vector" Proc. Natl. Acad. Sci. USA. Medical			
4	8. Flotte et al., (1995) "An improved capable of in vivo transduction" (system for packaging recombinant adeno-associated virus vectors Gene Ther. 2:29-37.			
4	9. Freshney, R.I. ed. (1987) in Anima Contents: pp. vii-xii.	al cell culture: a practical approach, IRL Press, Oxford, Table of			
5	0. Gait, M.J. ed. (1984) Oligonucleot Contents: pp.vii-xii.	ide synthesis. a practical approach, IRL Press, Oxford, Table of			
5		"Recombinant junctions formed by site-specific integration of some" J. Virol. 69(11):6917-6924.			
5		Site-specific integration by adeno-associated virus is directed by a atl. Acad. Sci. USA, Microbiology 91:10039-10043.			
5		(October 1984) "Use of adeno-associated virus as a mammalian of neomycin resistance into mammalian tissue culture cells" cs 81:6466-6470.			
5		Hermonat, P.L. et al., (August 1984) "Genetics of adeno-associated virus: Isolation and preliminary characterization of adeno-associated virus type 2 mutants" <i>J. Virol.</i> 51(2):329-339.			
		DATE CONCIDEDED.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92) Sheet 4 of 6 Docket Number 226272003901 Application Number 10/615,119 Form PTO 3449 MATION DISCLOSURE CITATION Applicant Carmel M. LYNCH et al. IN AN APPLICATION Filing Date July 7, 2003 Group Art Unit Not Yet Assigned (Use several sheets if necessary) Mailing Date September 2, 2003 Hölscher, C. et al., (1994) "Cell lines inducibly expressing the adeno-associated virus (AAV) rep 55. gene: Requirements for productive replication of rep-negative AAV mutants" J. Virol. 68(11):7169-7177. Hölscher, C. et al., (November 1995) "High-level expression of adeno-associated virus (AAV) rep78 56. or rep68 protein is sufficient for infectious-particle formation by a rep-negative AAV mutant" J. Virol. 69(11):6880-6885. Kaplitt, M.G. et al., (October 1994) "Long-term gene expression and phenotypic correction using 57. adeno-associated virus vectors in the mammalian brain" Nature Genetics 8:148-154. Kelman, Z. and O'Donnell, M. (1994) "DNA replication: Enzymology and mechanisms" Curr. Opin. 58. Genet. Dev. 4:185-195. Khleif, S.N. et al., (1991) "Inhibition of cellular transformation by the adeno-associated virus rep 59. gene" Virology 181:738-741. Kornberg, A. and Baker, T.A. (1992) DNA Replication, Second Edition, Freeman, W.H. & Co., New 60. York, Table of Contents: v-ix. Kotin, R.M. et al., (December 1992) "Characterization of a preferred site on human chromosone 19q 61. for integration of adeno-associated virus DNA by non-homologous recombination" The EMBO J. 11(13):5071-5078. Labow, M.A. et al., (April 1987) "Adeno-associated virus gene expression inhibits cellular 62. transformation by heterologous genes" Mol. Cell. Biol. 7(4):1320-1325. Laface, D. et al. (February 1988) "Gene transfer into hematopoietic progenitor cells mediated by an 63. adeno-associated virus vector" Virology 162(2):483-486. Laughlin, C.A. et al., (November 1979) "Spliced adenovirus-associated virus RNA" Proc. Natl. 64. Acad. Sci. USA Biochemistry 76(11):5567-5571. Laughlin, C.A. et al., (1983) "Cloning of infectious adeno-associated virus genomes in bacterial 65. plasmids" Gene 23:65-73. Lebkowski, J.S. et al., (October 1988) "Adeno-associated virus: A vector system for efficient 66. introduction and integration of DNA into a variety of mammalian cell types" Mol. Cell. Biol. 8(10):3988-3996. Linden, R.M. et al., (October 1996) "Site-specific integration by adeno-associated virus" Proc. Natl. 67. Acad. Sci. USA Colloquium Paper 93:11288-11294. Lupton, S.D. et al., (June 1991) "Dominant positive and negative selection using a hygromycin 68. phosphotransferase-thymidine kinase fusion gene" Molecular and Cellular Biology 11(6):3374-3378. Lynch, C.M. et al., (April 1997) "Adeno-associated virus vectors for vascular gene delivery" Circ. 69. Res. 80(4):497-505. McLaughlin, S.K. et al., (June 1988) "Adeno-associated virus general transduction vectors: Analysis 70. of proviral structures" J. Virol. 62(6):1963-1973.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa- 820862 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92) Sheet 5 of 6 Application Number 10/615,119 Docket Number 226272003901 Form PTQ THEORMATION DISCLOSURE CITATION **Applicant** Carmel M. LYNCH et al. IN AN APPLICATION Filing Date July 7, 2003 Group Art Unit Not Yet Assigned (Use several sheets if necessary) Mailing Date September 23 2003 Mendelson, E. et al., (1988) "Expression and rescue of a nonselected marker from an integrated AAV 71. vector" Virology 166:154-165. Miller, J.H. and Calos, M.P. eds., (1987) Current Communications in Molecular Biology, Gene 72. transfer vectors for mammalian cells, Cold Spring Harbor Laboratory, Table of Contents: vii-ix. Muro-Cacho, C.A. et al., (1992) "Gene transfer in human lymphocytes using a vector based on adeno-73. associated virus" J. Immunotherapy 11(4):231-237. Muzyczka, N. (1992) "Use of adeno-associated virus as a general transduction vector for mammalian 74. cells" Current Topics in Microbiol. and Immunol. 158:97-129. Rich, D.P. et al., (July 12, 1991) "Effect of deleting the R domain on CFTR-generated chloride *75*. channels" Science 253:205.207 Rose, J.A. (1974) "Chapter 1: Parvovirus reproduction" Comprehensive Virology 3:1-61. 76. Sambrook, J. et al., (1989) Molecular cloning: a laboratory manual, 2nd edition, Cold Spring Harbor 77. Laboratory Press, Table of Contents: xi-xxxviii. Samulski, R.J. et al., (September 1989) "Helper-free stocks of recombinant adeno-associated viruses: **78.** Normal integration does not require viral gene expression" J. Virol. 63(9):3822-3828. Samulski, R.J. et al., (March 1982) "Cloning of adeno-associated virus into pBR322: Rescue of intact 79. virus from the recombinant plasmid in human cells" Proc. Natl. Sci. USA Microbiology 79:2077-2081. Samulski, R.J. et al., (October 1987) "A recombinant plasmid from which an infectious adeno-80. associated virus genome can be excised in vitro and its use to study viral replication" J. Virol. 61(10):3096-3101. Senapathy, P. and Carter, B.J. (April 10, 1984) "Molecular cloning of adeno-associated virus variant 81. genomes and generation of infectious virus by recombination in mammalian cells" J. Biol. Chem. 259(7):4661-4666. Sheppard, D.N. et al., (March 25, 1994) "The amino-terminal portion of CFTR forms a regulated Cl **82**. channel" Cell 76:7091-1098. Simonsen, C.C. et al., (May 1983) "Isolation and expression of an altered mouse dihydrofolate 83. reductase cDNA" Proc. Natl. Acad. Sci. USA Biochemistry 80:2495-2499. Srivastava, A. et al., (February 1983) "Nucleotide sequence and organization of the adeno-associated 84. virus 2 genome" J. Virol. 45(2):555-564. Srivastiva, C.H. et al., (October 1989) "Construction of a recombinant human parvovirus B 19: 85. Adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B 19 hybrid virus" Proc. Natl. Acad. Sci. USA, Medical Sciences 86:8078-8082.

TOV	ARAT	MED.
EA	AIVII	NER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Sheet 6 of 6 Docket Number 226272003901 Application Number 10/615,119 CARREST ORMATION DISCLOSURE CITATION **Applicant** Carmel M. LYNCH et al. IN AN APPLICATION Filing Date July 7, 2003 Group Art Unit Not Yet Assigned (Use several sheets if necessary) Mailing Date September 23, 2003 Tratschin, J.-D. et al., (September 1984) "Genetic analysis of adeno-associated virus: Properties of 86. deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function" J. Virol. 51(3):611-619. Tratschin, J.-D. et al., (October 1984) "A human parvovirus, adeno-associated virus, as a eucaryotic 87. vector: Transient expression and encapsidation of the procaryotic gene for chloramphenicol acetyltransferase" Mol. Cell. Biol. 4(10):2072-2081. Tratschin, J.-D. et al., (November 1985) "Adeno-associated virus vector for high-frequency 88. integration, expression, and rescue of genes in mammalian cells" Moll. Cell. Biol. 5(11):3251-3260. Tratschin, J.-D. et al., (August 1986) "Negative and positive regulation in trans of gene expression 89. from adeno-associated virus vectors in mammalian cells by a viral rep gene product" Mol. Cell. Biol. 6(8):2884-2894. Urcelay, E. et al., (April 1995) "Asymetric replication in vitro from a human sequence element is 90. dependent on adeno-associated virus rep protein" J. Virol. 69(4):2038-2046. Vincent, K.A. et al., (1990) "Replication and packaging of HIV envelope genes in a novel adeno-91. associated virus vector system" Vaccines 90, Cold Spring Harbor Laboratory Press, Brown, F. et al. (eds.) pp. 353-359. Walsh, C.E. et al., (August 1992) "Regulated high level expression of a human y-globin gene 92. introduced into erythroid cells by an adeno-associated virus vector" Proc. Natl. Acad. Sci. USA Medical Sciences 89:7257-7261. Weir, D.M. ed. et al., (1996) "Immunochemistry and molecular immunology" in Weir's Handbook of 93. Experimental Immunology, Fifth Edition, Volume 1, Table of Contents: v-xii. Weitzman, M. D. et al., (June 1994) "Adeno-associated virus (AAV) rep proteins mediate complex 94. formation between AAV DNA and its integration site in human DNA" Proc. Natl. Acad. Sci. USA Biochemistry 91:5808-5817. Wong, K.K. et al., (1991) "Restriction of HSV-1 production in cell lines transduced with an antisense 95. viral vector targeting the ICP4 gene" Vaccines 91, Cold Spring Harbor Laboratory Press, pp. 183-189. Xiao, X. (Feb. 1997). "A Novel 165-Base-Pair Terminal Repeat Sequence Is the Sole cis Requirement 96. for the Adeno-Associated Virus Life Cycle," Journal of Virology 71(2):941-948. DATE CONSIDERED: **EXAMINER:**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) pa- 820862

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE